A new system for targeted delivery of doxorubicin into tumor cells

Yabbarov, N. G.; Посыпанова, Г. А.; Vorontsov, E. A.; Obydenny, S.I.; Severin, E. S.

doi:10.1016/j.jconrel.2013.03.007

Cited by 47 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…65 Russian researchers have shown that recombinant domain III of AFP (rAFP-3D) does not differ from the fulllength protein by its ability to bind to and penetrate into cancer cells. 65,82,114,115 This has enabled the conclusion that that recombinant protein fragments based on C-terminal domain III of AFP can be used for targeted drug delivery. 65,82,114,115 The doxorubicin conjugate with rAFP-3D has shown the high efficacy against doxorubicin-sensitive cell line SKOV3 and against resistant cell line SKVLB; at the same time, the toxicity to human peripheral blood lymphocytes is low.…”

Section: Viii2 Structure Of Alpha-fetoproteinmentioning

confidence: 99%

New approaches to targeted drug delivery to tumour cells

Severin¹

2015

Russ. Chem. Rev.

View full text Add to dashboard Cite

Section: Viii2 Structure Of Alpha-fetoproteinmentioning

confidence: 99%

New approaches to targeted drug delivery to tumour cells

Severin¹

2015

Russ. Chem. Rev.

View full text Add to dashboard Cite

“…2 Compared with other efforts, the nanocarriers can overcome the MDR by multiple approaches and attract more attention. 3,4 Nanocarriers, such as polymeric micelles, 5 liposomes, 6 nanoparticles, 7 and dendrimers, 8 are widely used to combat MDR in cancer.…”

Section: Introductionmentioning

confidence: 99%

The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells

Zhang¹,

Liú²,

Zhang³

et al. 2016

IJN

View full text Add to dashboard Cite

Polyamidoamine dendrimers, which can deliver drugs and genetic materials to resistant cells, are attracting increased research attention, but their transportation behavior in resistant cells remains unclear. In this paper, we performed a systematic analysis of the cellular uptake, intracellular transportation, and efflux of PAMAM-NH 2 dendrimers in multidrug-resistant breast cancer cells (MCF-7/ADR cells) using sensitive breast cancer cells (MCF-7 cells) as the control. We found that the uptake rate of PAMAM-NH 2 was much lower and exocytosis of PAMAM-NH 2 was much greater in MCF-7/ADR cells than in MCF-7 cells due to the elimination of PAMAM-NH 2 from P-glycoprotein and the multidrug resistance-associated protein in MCF-7/ADR cells. Macropinocytosis played a more important role in its uptake in MCF-7/ADR cells than in MCF-7 cells. PAMAM-NH 2 aggregated and became more degraded in the lysosomal vesicles of the MCF-7/ADR cells than in those of the MCF-7 cells. The endoplasmic reticulum and Golgi complex were found to participate in the exocytosis rather than endocytosis process of PAMAM-NH 2 in both types of cells. Our findings clearly showed the intracellular transportation process of PAMAM-NH 2 in MCF-7/ADR cells and provided a guide of using PAMAM-NH 2 as a drug and gene vector in resistant cells.

show abstract

“…Second, although nanoparticles 26 are expected to reach tumors by the effect of enhanced 27 permeability and retention (EPR), their nonspecific uptake by 28 mononuclear phagocytic cells that are present in the liver, spleen, 29 and lungs may limit the effectiveness of therapeutic drugs and 30 cause severe side effects. [2][3][4] Third, anticancer agents should be 31 effectively transported into tumor cells to exhibit their 32 pharmacological activity. However, in some cases, completion 33 of this endocytosis process is difficult, resulting in an insufficient 34 intracellular drug accumulation and a poor treatment efficacy.…”

mentioning

confidence: 99%